"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 53: | Line 53: | ||
<br> | <br> | ||
</div> | </div> | ||
| + | </center> | ||
</html> | </html> | ||
:*Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] | :*Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] | ||
:*Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | :*Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | ||
|} | |} | ||
Revision as of 09:59, 28 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Dr. Lluis M. Mir
- Dr. Karim Benihoud
INSERM U872
- Dr. Srinivas Kaveri
AnyGenes
- Dr. Benyoussef Naimi
National Reference Center for Mycobacteria and the Resistance of Mycobacteria to Antituberculosis from CHU Pitié-Salpêtrière
- Dr. Nicolas Veziris
Our Sponsors
